MARKET

CASI

CASI

CASI Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.630
-0.010
-0.61%
Opening 15:44 05/06 EDT
OPEN
1.630
PREV CLOSE
1.640
HIGH
1.650
LOW
1.560
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
1.460
MARKET CAP
227.87M
P/E (TTM)
-3.7925
1D
5D
1M
3M
1Y
5Y
This Day In Market History: New York Times Article Suggests Cancer Cure By Year 2000
Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date. What Happened? On this day in 1998, a front-page New York Times report suggested EntreMed was two years away from curing cancer in humans.
Benzinga · 3d ago
8-K: CASI Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- 0000895051 false 0000895051 2021-04-27 2021-04-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383%
Apr 30, 2021 (Penny Stocks via COMTEX) -- Analysts Say These Penny Stocks Are A Buy. Do You Agree? If you're looking for penny stocks to buy, there are...
Penny Stocks · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 04/28 16:53
These 2 Penny Stocks Could Rally Over 100%, Says Oppenheimer
Speaking of economic opportunity, and the general benefits of wide-ranging growth, President John Kennedy once said, “A rising tide lifts all boats.” As the COVID cris...
TipRanks.com · 04/28 14:39
58 Biggest Movers From Yesterday
Gainers
Benzinga · 04/27 09:03
38 Stocks Moving In Monday's Mid-Day Session
Gainers
Benzinga · 04/26 16:09
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
 
Benzinga · 04/26 14:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CASI. Analyze the recent business situations of CASI Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CASI stock price target is 4.100 with a high estimate of 5.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 42.23M
% Owned: 30.21%
Shares Outstanding: 139.80M
TypeInstitutionsShares
Increased
30
3.54M
New
12
196.63K
Decreased
17
1.77M
Sold Out
6
141.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.80%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Wei-Wu He
President
Wei Zhang
Chief Financial Officer/Chief Accounting Officer
Weihao Xu
Other
Alexander Zukiwski
Independent Director
James Huang
Independent Director
Franklin Salisbury
Independent Director
Rajesh Shrotriya
Independent Director
Y. Alexander Wu
Independent Director
Quan Zhou
No Data
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.